Filter by
Selections
August 27, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
Read MoreAugust 13, 2025
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
Read MoreAugust 1, 2025
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Read MoreJuly 28, 2025
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
Read MoreJuly 24, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 23, 2025
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
Read MoreJuly 8, 2025